Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Bulis Veronica Sanchez 2. Date of Event Requiring Statement (Month/Day/Year) 10/31/2025 3. Issuer Name and Ticker or Trading Symbol Lyell Immunopharma, Inc. [LYEL] (Last) (First) (Middle) C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) VP, Corporate Controller 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) SOUTH SAN FRANCISCO, CA 94080 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 9,452(1) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(2)	02/23/2033	Common Stock	1,674	$42.6	D
Option (right to buy)	(3)	03/15/2032	Common Stock	624	$37.4	D
Option (right to buy)	(4)	09/09/2031	Common Stock	3,000	$37.4	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Bulis Veronica Sanchez C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY, SUITE 101 SOUTH SAN FRANCISCO, CA 94080			VP, Corporate Controller

Signatures

/s/ Mark Meltz, Attorney-in-Fact		11/10/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Includes restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting and will be settled in common stock subject to vesting as follows: (1) 38 shares that will vest quarterly over the six-month period following August 9, 2025; (2) 312 shares that will vest quarterly over the eighteen-month period following August 9, 2025; (3) 2,516 shares that vest quarterly over the thirty month period following August 9, 2025 and (4) 3,937 shares that vest quarterly over the forty-two-month period following August 9, 2025; in each case, subject to the reporting person providing service through the applicable vesting date.
(2)	12.5% of the option shares vested on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
(3)	12.5% of the option shares vested on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
(4)	Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.